LNG Energy Group Corp. - MCURF STOCK NEWS

Mind Cure Health has officially been included in the AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol PSIL. This ETF focuses on biotechnology and pharmaceutical companies involved in the emerging psychedelics medicine industry. Kelsey Ramsden, President and CEO, stated that this inclusion validates the company's strategy to integrate digital therapeutics with psychedelic medicine to enhance mental health. The recognition aims to increase investor awareness of Mind Cure's innovative approaches to mental health treatment.

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) announced its participation as a Platinum Sponsor at the 2021 SANA Symposium, a significant event for mental health professionals to engage with emerging psychedelic therapies. The conference, scheduled for September 17-19, 2021, will feature Mind Cure's digital therapeutics platform, iSTRYM, aimed at enhancing psychedelic-assisted psychotherapy. With approximately 2000 industry professionals expected, the event highlights the growing interest in psychedelic treatments for mental health issues like depression and PTSD.

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) announced that Kelsey Ramsden, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be accessible starting September 13, 2021, at 7:00 A.M. Eastern Time and available via a webcast for 90 days. MINDCURE focuses on innovating and commercializing new mental health therapies, including digital therapeutics and psychedelic compounds.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) reported its financial results for the year ending May 31, 2021. Key highlights include net proceeds of $27.2 million from share issuances, and a net loss of $10.2 million, attributed to operating expenses. The company launched iSTRYM, a digital therapeutic tool, and filed several provisional patent applications, including for synthetic ibogaine. As of May 31, 2021, the cash position was $18.3 million. The CEO emphasized the solid foundation for future developments in psychedelic research and digital therapeutics.

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) has appointed Dr. Ken Weingardt as a Senior Clinical Technology Advisor for its digital therapeutics platform, iSTRYM. Dr. Weingardt's expertise will guide iSTRYM towards clinical excellence and commercial deployment, scheduled for Q1 2022. The platform is designed to improve patient-therapist interactions through evidence-backed protocols and real-time assessments. Mind Cure aims to file for FDA approval, enhancing its market presence in the growing psychedelics sector.

MINDCURE has appointed Jerry White, a humanitarian activist and 1997 Nobel Peace Prize co-recipient, as an advisor. White, known for leading impactful campaigns and helping victims of war, aims to enhance MINDCURE's mission to transform mental health treatments via science-backed psychedelic medicines. The company also announced the granting of stock options totaling 305,000 to employees and consultants at prices ranging from $0.415 to $0.465 per share. This strategic move reflects MINDCURE's commitment to advancing mental health solutions globally.

Mind Cure Health has initiated the second stage of manufacturing pharmaceutical-grade ibogaine for clinical research. This stage focuses on evaluating the quality and scaling up production for commercial viability. The company is also pursuing patent applications for two synthesis methods to enhance ibogaine's purity. Ibogaine, derived from the iboga tree, shows potential for treating addiction and neurological conditions. The successful production of synthetic ibogaine aims to provide researchers and clinicians with a consistent and reliable supply for future therapeutic applications.

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) announced the filing of provisional patent applications for innovative synthesis methods of ibogaine, which could enhance the quality and reliability of this psychedelic drug for research purposes. Two chemical synthesis routes have shown promise, aiming to improve isomeric and chiral purity. Further development will focus on scaling up the manufacturing process to support clinical trials and potential therapeutic uses for addiction treatment. MINDCURE also entered an agreement with Investor Brand Network for marketing services.

Mind Cure Health has adopted an Advance Notice Policy for director nominations, effective immediately. This policy aims to enhance shareholder engagement by providing clear guidelines for submitting nominations, ensuring timely communication, and facilitating informed voting. Nominations must be submitted 30 to 65 days before annual meetings or within specific timeframes for special meetings. The policy will be presented for shareholder approval at the upcoming annual general meeting on September 7, 2021. For more details, visit mindcure.com.